RxDoctor Payments Data

Bhawna Bahethi, MD

Internal Medicine · Glen Burnie, MDNPI 1629150586

Payments from drug & device makers

$3,846in general payments, 2019–2025

Across 213 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$969
  • AstraZeneca$320
  • Novo Nordisk$312
  • Pfizer$266
  • Astellas Pharma US Inc$250
  • Lilly USA, LLC$234
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,77198%
  • Education$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,846 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$266,593
Medicare patients
497
Services billed
4,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$91,169
OzempicSemaglutide37$67,243
JardianceEmpagliflozin27$40,146
TrulicityDulaglutide14$26,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$26,851
JanuviaSitagliptin Phosphate19$24,352
XareltoRivaroxaban13$20,110
EntrestoSacubitril/Valsartan18$19,398
LinzessLinaclotide13$17,585
FarxigaDapagliflozin Propanediol19$13,984
MyrbetriqMirabegron13$8,475
Rosuvastatin Calcium256$7,461
Atorvastatin Calcium452$6,612
Metoprolol Succinate199$5,698
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$266$91,16968 claims
Novo NordiskOzempic$312$67,24337 claims
Boehringer IngelheimJardiance$96$40,14627 claims
GSKTrelegy Ellipta, Anoro Ellipta$182$32,08839 claims
Lilly USA, LLCTrulicity$234$26,94514 claims
MerckJanuvia$62$24,35219 claims
NovartisEntresto$134$19,39818 claims
AbbVieLinzess$969$17,58513 claims
AstraZenecaFarxiga$320$13,98419 claims
Astellas Pharma US IncMyrbetriq$250$8,47513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →